Severity
Moderate
FDA Drug recall · Reported April 12, 2023
cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.
Preferred Pharmaceuticals, Inc. recalled Rosuvastatin Tablets, USP, 10 mg, Packaged as: a) 30-count bottle (NDC 68788-7086-3); b) … - a moderate-severity action.
Rosuvastatin Tablets, USP, 10 mg, Packaged as: a) 30-count bottle (NDC 68788-7086-3); b) … was recalled by Preferred Pharmaceuticals, Inc. in April 12, 2023. Reason: cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.. Check the official notice for the remedy. Verify recall #D-0519-2023 with the FDA Drug before acting.
The recall
Preferred Pharmaceuticals, Inc. issued this moderate-severity FDA Drug recall-cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection..
Sourced from official FDA Drug enforcement records. Verify recall #D-0519-2023 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0519-2023) was formally reported on April 12, 2023, with the manufacturer initiating the action on March 23, 2023. It is classified under Moderate severity (Class II), with a current status of Ongoing. Preferred Pharmaceuticals, Inc. is listed as the recalling firm, operating out of Anaheim, CA. Federal records list the affected scope as a) 59 Bottles, b) 77 Bottles.
The documented reason for this recall is: cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection. Distribution data in the federal record shows the product reached: USA Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 3,731 children & baby products recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
a) 59 Bottles, b) 77 Bottles
Related Recalls
6
0 from same agency
Rosuvastatin Tablets, USP, 10 mg, Packaged as: a) 30-count bottle (NDC 68788-7086-3); b) 90-count bottle (NDC 68788-7086-9), Rx only, Manufactured: Accord Healthcare, Inc., Durham, NC 27703.
cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Ongoing |
| Recall number | D-0519-2023 |
| Date reported | April 12, 2023 |
| Date initiated | March 23, 2023 |
| Recalling firm | Preferred Pharmaceuticals, Inc. |
| Firm location | Anaheim, CA |
| Affected scope | a) 59 Bottles, b) 77 Bottles |
| Distribution | USA Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Xishentang Dongguan Trading Co, Ltd., dba Pretty-Life, of China · 2026-07-02
Diamond Wipes International, Inc. of Chino, California · 2026-07-02
· 2026-07-02
· 2026-07-02
Sanven Technology Ltd., dba Vevor, of Rancho Cucamonga, California · 2026-07-02
Compare this recall with AMASKY Nursing Pillows Recalled Due to Risk of Serious Inju… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported April 12, 2023. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.